Sellas Life Sciences Group Inc SLS:NASDAQ

Last Price$5.07NASDAQ Previous Close - Last Trade as of 4:00PM ET 1/21/22

Today's Change-0.23(4.34%)
Bid (Size)$5.02 (1)
Ask (Size)$5.50 (2)
Day Low / High$5.01 - 5.35
Volume155.9 K
 

View Biotechnology IndustryPeer Comparison as of 01/21/2022

 

Sellas Life Sciences Group Inc ( NASDAQ )

Price: $5.07
Change: -0.23 (4.34%)
Volume: 155.9 K
4:00PM ET 1/21/2022
 
 

AVROBIO Inc ( NASDAQ )

Price: $1.83
Change: -0.03 (1.61%)
Volume: 886.0 K
4:00PM ET 1/21/2022
 
 

Applied Therapeutics Inc ( NASDAQ )

Price: $3.17
Change: -0.23 (6.76%)
Volume: 348.0 K
4:00PM ET 1/21/2022
 
 

Entasis Therapeutics Holdings Inc ( NASDAQ )

Price: $1.74
Change: -0.10 (5.43%)
Volume: 108.9 K
4:00PM ET 1/21/2022
 
 

Trevena Inc ( NASDAQ )

Price: $0.52
Change: -0.03 (4.73%)
Volume: 1.3 M
4:00PM ET 1/21/2022
 

Read more news Recent News

Top Premarket Gainers
8:20AM ET 1/05/2022 MT Newswires

Mainz Biomed (MYNZ) shares soared 83% after the company acquired exclusive rights to a portfolio of mRNA biomarkers for potential use in cancer detection...

--Cantor Fitzgerald Adjusts Price Target on SELLAS Life Sciences to $16 From $18, Reiterates Overweight Rating
11:39AM ET 12/03/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

--Cantor Fitzgerald Starts SELLAS Life Sciences Group at Overweight With $18 Price Target
6:27AM ET 7/21/2021 MT Newswires

(MT Newswires covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may...

Sellas Reports 'Promising' Galinpepimut-S Data For Treating Advanced Metastatic Ovarian Cancer
2:59PM ET 6/30/2021 MT Newswires

Sellas Life Sciences (SLS) said a phase 1/2 study of its drug candidate galinpepimut-S, or GPS, yielded "promising" data in the treatment of a certain type...

Company Profile

Business DescriptionSELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company. It engages in the development and commercialization of immunotherapeutic for cancer indications. The firm's product pipeline includes galinpepimut-S and nelipepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY. View company web site for more details
Address7 Times Square
New York, New York 10036
Phone+1.646.200.5278
Number of Employees8
Recent SEC Filing12/16/20218-K
President, Chief Executive Officer & DirectorAngelos M. Stergiou
Chief Accounting Officer & Senior VP-FinanceJohn T. Burns
Senior Vice President-Clinical DevelopmentDragan Cicic
Secretary, Executive VP & General CounselBarbara A. Wood

Company Highlights

Price Open$5.22
Previous Close$5.30
52 Week Range$5.01 - 15.08
Market Capitalization$80.5 M
Shares Outstanding15.9 M
SectorHealth Technology
IndustryBiotechnology
Next Earnings Announcement03/22/2022

Options Summary

Call Open Interest (1d)*
Put Open Interest (1d)*
Call Volume (1d)*
Put Volume (1d)*
Put Call Open Interest Ratio (1d)*
Put Call Volume Ratio (1d)*
* Data delayed by up to 15 minutes

View all fundamentalsFundamentals

Price / EarningsN/A
Earnings per Share-$1.19
Beta vs. S&P 500N/A
Revenue$0.00
Net Profit Margin-187.55%
Return on Equity-61.06%

Analyst Ratings as of 07/20/2021

Buy
3
Overweight
0
Hold
0
Underweight
0
Sell
0
Consensus RecommendationConsensus Icon
Powered by Factset